RT Journal Article SR Electronic T1 RIC3 variants are not associated with Parkinson’s Disease in large European, Latin American, or East Asian cohorts JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.22.21259012 DO 10.1101/2021.06.22.21259012 A1 Kajsa Brolin A1 Sara Bandres-Ciga A1 Hampton Leonard A1 Mary B. Makarious A1 Cornelis Blauwendraat A1 Ignacio F Mata A1 Jia Nee Foo A1 Lasse Pihlstrøm A1 Maria Swanberg A1 Ziv Gan-Or A1 Manuela MX Tan A1 International Parkinson’s Disease Genomics Consortium (IPDGC) YR 2021 UL http://medrxiv.org/content/early/2021/06/28/2021.06.22.21259012.abstract AB Parkinson’s disease (PD) is a complex neurodegenerative disorder in which both rare and common genetic variants contribute to disease risk. Multiple genes have been reported to be linked to monogenic PD, but these only explain a fraction of the observed familial aggregation. Rare variants in RIC3 have been suggested to be associated with PD in the Indian population. However, replication studies yielded inconsistent results. We further investigate the role of RIC3 variants in PD in European cohorts using individual-level genotyping data from 14,671 PD patients and 17,667 controls, as well as whole-genome sequencing data from 1,615 patients and 961 controls. We also investigated RIC3 using summary statistics from a Latin American cohort of 1,481 individuals, and from a cohort of 31,575 individuals of East Asian ancestry. We did not identify any association between RIC3 and PD in any of the cohorts. However, more studies of rare variants in non-European ancestry populations, in particular South Asian populations, are necessary to further evaluate the world-wide role of RIC3 in PD etiology.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/ipdgc/IPDGC-Trainees/blob/master/RIC3.ipynb Funding StatementThis work was supported in part by the Norwegian South-East Regional Health Authority (Helse Sor-Ost RHF) (supporting MMXT and LP) and in part by the Swedish Research Council (VR) and Ake Wiberg's foundation (supporting KB and MS). We would also like to thank the Accelerating Medicines Partnership - Parkinson's disease (AMP-PD). Data used in preparation of this article were obtained from the AMP-PD Knowledge Platform in which the clinical data and biosamples were obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). The investigators for each cohort have not participated in reviewing the data analysis or content of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in preparation of this article were obtained from the publicly available, but controlled access, data from the Accelerating Medicines Partnership - Parkinson's disease (AMP-PD) Knowledge Platform in which the clinical data and biosamples were obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). AMP-PD has approved the study. As the analyses in this manuscript utitlize secondary analyses of suitably anonymized datasets, they do not require ethics committee review. The respective ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent in the original publications for the datasets used. The details of these studies can be obtained from the AMP PD website (https://amp-pd.org) and each study websiteAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in preparation of this article were obtained from the AMP-PD Knowledge Platform in which the clinical data and biosamples were obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). The investigators for each cohort have not participated in reviewing the data analysis or content of the manuscript. All code for these analyses is available at: https://github.com/ipdgc/IPDGC-Trainees/blob/master/RIC3.ipynb. https://www.amp-pd.org